Immunotoxicology of Biological Response Modifiers

作者: J.L. Bussiere

DOI: 10.1016/B978-0-08-046884-6.00630-8

关键词:

摘要: Biological response modifiers (BRMs) are natural proteins that alter immune responses and have been developed as either immunosuppressive or immunostimulating drugs. These may include products such β-glucans, biotherapeutics monoclonal antibodies. Immunotoxicity testing of these modulators is not currently regulated by International Conference on Harmonization (ICH) guidelines thus, many the standard immunotoxicity tests used for understanding pharmacology molecule. Since only cross-reactive in nonhuman primates (NHPs), need to be adapted (since rodents species small-molecule therapeutics). Unanticipated effects system related mechanism action, but would then considered immunotoxicity. Immunogenicity must also assessed, which drug. All factors make BRMs a challenge toxicologists working this field.

参考文章(63)
Eric Wakshull, Deborah Brunke-Reese, Johanna Lindermuth, Leslie Fisette, Robin S. Nathans, John J. Crowley, Jeffrey C. Tufts, Janet Zimmerman, William Mackin, David S. Adams, PGG-Glucan, a soluble β-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-κB-like factor in human PMN: Evidence for a glycosphingolipid β-(1,3)-glucan receptor Immunopharmacology. ,vol. 41, pp. 89- 107 ,(1999) , 10.1016/S0162-3109(98)00059-9
E. Kimby, H. Mellstedt, B. Nilsson, M. Björkholm, G. Holm, C. Lindemalm, B. Tribukait, Blood lymphocyte characteristics as predictors of prognosis in chronic lymphocytic leukemia of B-cell type Hematological Oncology. ,vol. 6, pp. 47- 55 ,(1988) , 10.1002/HON.2900060108
Huub Schellekens, Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clinical Therapeutics. ,vol. 24, pp. 1720- 1740 ,(2002) , 10.1016/S0149-2918(02)80075-3
Junzhi Li, Chun Yang, Yuping Xia, Amy Bertino, John Glaspy, Michael Roberts, David J. Kuter, Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. ,vol. 98, pp. 3241- 3248 ,(2001) , 10.1182/BLOOD.V98.12.3241
Joanna Saluk-Juszczak, Karolina Królewska, Barbara Wachowicz, Response of blood platelets to beta-glucan from Saccharomyces cerevisiae. Platelets. ,vol. 21, pp. 37- 43 ,(2010) , 10.3109/09537100903359306
Jennifer Sims, Assessment of biotechnology products for therapeutic use Toxicology Letters. ,vol. 120, pp. 59- 66 ,(2001) , 10.1016/S0378-4274(01)00310-1
Carolyn L. Bigbee, Daryl G. Gonchoroff, George Vratsanos, Steven G. Nadler, Helen G. Haggerty, JoAnne L. Flynn, Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis & Rheumatism. ,vol. 56, pp. 2557- 2565 ,(2007) , 10.1002/ART.22750
G. KÖHLER, C. MILSTEIN, Continuous cultures of fused cells secreting antibody of predefined specificity Nature. ,vol. 256, pp. 495- 497 ,(1975) , 10.1038/256495A0
Hervé Lebrec, Laine Cowan, Michelle Lagrou, Cecile Krejsa, Moni B. Neradilek, Nayak L. Polissar, Lauren Black, Jeanine Bussiere, An inter-laboratory retrospective analysis of immunotoxicological endpoints in non-human primates: T-cell-dependent antibody responses. Journal of Immunotoxicology. ,vol. 8, pp. 238- 250 ,(2011) , 10.3109/1547691X.2011.587473
Carol Ezzell, Magic bullets fly again. Scientific American. ,vol. 285, pp. 34- 41 ,(2001) , 10.1038/SCIENTIFICAMERICAN1001-34